Molecular pathogenesis of urothelial carcinoma the clinical utility of emerging new biomarkers and future molecular classification of bladder cancer

Analytical and Quantitative Cytology and Histology

Volumn 31, Issue 1, 2009, Pages 5-16

  Lacy, Shanon ^a   Lopez Beltran, Antonio ^b   MacLennan, Gregory T ^c   Foster, Stephanie R ^d   Montironi, Rodolfo ^e   Cheng, Liang ^a,f  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CÓRDOBA   (Spain)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY   (United States)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^f Laboratory Medicine   (United States)

Author keywords

Biomarkers; Bladder cancer; Molecular genetics

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FRAGILE HISTIDINE TRIAD PROTEIN; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; TUMOR MARKER;

BLADDER CANCER; CANCER CLASSIFICATION; CANCER GROWTH; CANCER SCREENING; CANCER SURVIVAL; CHROMOSOME 8; CHROMOSOME 9; CHROMOSOME ABERRATION; CHROMOSOME DELETION; GENE MUTATION; GENETIC MARKER; HEALTH CARE COST; HETEROZYGOSITY LOSS; HUMAN; MICROSATELLITE INSTABILITY; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR GROWTH;

ACID ANHYDRIDE HYDROLASES; ALLELIC IMBALANCE; CHROMOSOMES, HUMAN, PAIR 8; CHROMOSOMES, HUMAN, PAIR 9; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; NEOPLASM PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RETINOBLASTOMA PROTEIN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 61849133968     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (141)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96
2. Cheng L, Lopez-Beltran A, MacLennan GT, Montironi R, Bostwick DG: Neoplasms of the urinary bladder. In Uro-logic Surgical Pathology. Second edition. Edited by DG Bostwick, L Cheng. Philadelphia, Elsevier/Mosby, 2008, pp 259-352
3. Eble JN, Sauter G, Epstein JI, Sesterhenn IA: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, IARC Press, 2004
4. Denzinger S, Mohren K, Knuechel R, Wild PJ, Burger M, Wieland WF, Hartmann A, Stoehr R: Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses. Hum Pathol 2006;37:143-151
5. Cheng L, Cheville JC, Neumann RM, Bostwick DG: Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol 1999;23:443-447
6. Cheng L, Cheville JC, Neumann RM, Bostwick DG: Flat intraepithelial lesions of the urinary bladder. Cancer 2000;88: 625-631
7. Cheng L, Cheville JC, Neumann RM, Leibovich BC, Egan KS, Spotts BE, Bostwick DG: Survival of patients with carcinoma in situ of the urinary bladder. Cancer 1999;85:2469-2474
8. Schulz WA: Understanding urothelial carcinoma through cancer pathways. Int J Cancer 2006;119:1513-1518
9. Cheng L, Neumann RM, Weaver AL, Spotts BE, Bostwick DG: Predicting cancer progression in patients with stage Tl bladder carcinoma. J Clin Oncol 1999;17:3182-3187
10. Borden LS Jr, Clark PE, Hall MC: Bladder cancer. Curr Opin Oncol 2004;16:257-262
11. Soloway MS: Progression and survival in patients with T1G3 bladder tumors. Urology 2002;59:631
12. Mhawech-Fauceglia P, Cheney RT, Schwaller J: Genetic alterations in urothelial bladder carcinoma: An updated review. Cancer 2006;106:1205-1216
13. Steinberg GD, Trump DL, Cummings KB: Metastatic bladder cancer: Natural history, clinical course, and consideration for treatment. Urol Clin North Am 1992;19:735-746
14. Liebert M, Seigne J: Characteristics of invasive bladder cancers: Histological and molecular markers. Semin Urol Oncol 1996;14:62-72
15. Pfister C, Chautard D, Devonec M, Perrin P, Chopin D, Rischmann P, Bouchot O, Beurton D, Coulange C, Ram-beaud JJ: Immunocyt test improves the diagnostic accuracy of urinary cytology: Results of a French multicenter study. J Urol 2003;169:921-924
16. Bastacky S, Ibrahim S, Wilczynski SP, Murphy WM: The accuracy of urinary cytology in daily practice. Cancer 1999; 87:118-128
17. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH: Tumor markers in the diagnosis of primary bladder cancer: A systematic review. J Urol 2003;169:1975-1982
18. Wu XR: Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 2005;5:713-725
19. Dalbagni G, Presti J, Reuter V, Fair WR, Cordon-Cardo C: Genetic alterations in bladder cancer. Lancet 1993;342:469-471
20. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG: Allelotype of human bladder cancer. Cancer Res 1994;54:531-538
21. Rosin MP, Cairns P, Epstein JI, Schoenberg MP, Sidransky D: Partial allelotype of carcinoma in situ of the human bladder. Cancer Res 1995;15:5213-5216
22. Cheng L, MacLennan GT, Pan CX, Jones TD, Moore CR, Zhang S, Gu J, Patel NB, Kao C, Gardner TA: Allelic loss of the active X chromosome during bladder carcinogenesis. Arch Pathol Lab Med 2004;128:187-190
23. Cheng L, MacLennan GT, Zhang S, Wang M, Pan CX, Koch MO: Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder. Cancer 2004; 101:183-188
24. Cheng L, Jones TD, McCarthy RP, Eble JN, Wang M, MacLennan GT, Lopez-Beltran A, Yang XJ, Koch MO, Zhang S, Pan CX, Baldridge LA: Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol 2005;166:1533-1539
25. Jones TD, Wang M, Eble JN, MacLennan GT, Lopez-Beltran A, Zhang S, Cocco A, Cheng L: Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res 2005;11:6512-6519
26. Jones TD, Carr MD, Eble JN, Wang M, Lopez-Beltran A, Cheng L: Clonal origin of lymph node metastases in bladder carcinoma. Cancer 2005;104:1901-1910
27. Sung MT, Eble JN, Wang M, Tan PH, Lopez-Beltran A, Cheng L: Inverted papilloma of the urinary bladder: A molecular genetic appraisal. Mod Pathol 2006;19:1289-1294
28. Sung MT, Wang M, MacLennan GT, Eble JN, Tan PH, Lopez-Beltran A, Montironi R, Harris JJ, Kuhar M, Cheng L: Histogenesis of sarcomatoid urothelial carcinoma of the urinary bladder: Evidence for a common clonal origin with divergent differentiation. J Pathol 2007;211:420-430
29. Sung MT, Zhang S, MacLennan GT, Lopez-Beltran A, Montironi R, Wang M, Tan PH, Cheng L: Histogenesis of clear cell adenocarcinoma in the urinary tract: Evidence of urothelial origin. Clin Cancer Res 2008;14:1947-1955
30. Jones TD, Zhang S, Lopez-Beltran A, Eble JN, Sung MT, MacLennan GT, Montironi R, Tan PH, Zheng S, Baldridge LA, Cheng L: Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in-situ hybridization, immunohisto-chemistry, and morphologic analysis. Am J Surg Pathol 2007;31:1861-1867
31. Prat E, Bernues M, Caballin MR, Egozcue J, Gelabert A, Miro R: Detection of chromosomal imbalances in papillary bladder tumors by comparative genomic hybridization. Urology 2001;57:986-992
32. Simon R, Burger H, Brinkschmidt C, Bocker W, Hertle L, Terpe HJ: Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J Pathol 1998; 185:345-351
33. Richter J, Wagner U, Schraml P, Maurer R, Alund G, Knonagel H, Moch H, Mihatsch MT, Gasser TC, Sauter G: Chromosomal imbalances are associated with a high risk of progression in early invasive (pTl) urinary bladder cancer. Cancer Res 1999;59:5687-5691
34. Simon R, Burger H, Semjonow A, Hertle L, Terpe HJ, Bock-er W: Patterns of chromosomal imbalances in muscle invasive bladder cancer. Int J Oncol 2000;17:1025-1029
35. Bruch J, Wohr G, Hautmann R, Mattfeldt T, Bruderlein S, Moller P, Sauter S, Hameister H, Vogel W, Paiss T: Chromosomal changes during progression of transitional cell carcinoma of the bladder and delineation of the amplified interval on chromosome arm 8q. Genes Chromosomes Cancer 1998;23:167-174
36. Richter J, Jiang F, Gorog JP, Sartorius G, Egenter C, Gasser TC, Moch H, Mihatsch MJ, Sauter G: Marked genetic differences between stage pTa and stage pTl papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 1997;57:2860-2864
37. Richter J, Beffa L, Wagner U, Schraml P, Gasser TC, Moch H, Mihatsch MJ, Sauter G: Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am J Pathol 1998;153: 1615-1621
38. Koga F, Kawakami S, Fujii Y, Saito K, Ohtsuka Y, Iwai A, Ando N, Takizawa T, Kageyama Y, Kihara K: Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 2003;9:5501-5507
39. Fadl-Elmula I, Gorunova L, Mandahl N, Elfving P, Lund- gren R, Mitelman F, Heim S: Karyotypic characterization of urinary bladder transitional cell carcinomas. Genes Chromosomes Cancer 2000;29:256-265
40. Cairns P, Shaw ME, Knowles MA: Initiation of bladder cancer may involve deletion of a tumor suppressor gene on chromosome 9. Oncogene 1993;8:1083-1085
41. Ruppert JM, To kino K, Sidransky D: Evidence for two bladder cancer suppressor loci on human chromosome 9. Cancer Res 1993;53:5093-5095
42. Bakkar AA, Wallerand H, Radvanyi F, Lahaye J-B, Pissard S, Lecerf L, Kouyoumdjian JC, Abbou CC, Pairon JC, Jourand MC, Thiery JP, Chopin DK, Gil Diez de Medina S: FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003;63:8108-8112
43. van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boeve ER, Jobsis AC, Zwarthoff EC: FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004;64:1911-1914
44. Lamy A, Gobet F, Laurent M, Blanchard F, Varin C, Moulin C, Andreou A, Frebourg T, Pfister C: Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. J Urol 2006;176:2686-2689
45. Mhawech-Fauceglia P, Cheney RT, Fischer G, Beck A, Herrmann FR: FGFR3 and p53 protein expressions in patients with pTa and pTl urothelial bladder cancer. Eur J Surg Oncol 2006;32:231-237
46. Natrajan R, Louhelainen J, Williams S, Laye J, Knowles MA: High-resolution deletion mapping of 15ql3.2-q21.1 in transitional cell carcinoma of the bladder. Cancer Res 2003;63: 7657-7662
47. Shaw ME, Knowles MA: Deletion mapping of chromosome 11 in carcinoma of the bladder. Genes Chromosomes Cancer 1995;13:1-8
48. Tsai YC, Nichols PW, Hiti AL, Williams Z, Skinner DG, Jones PA: Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res 1990;50:44-47
49. Aveyard JS, Skilleter A, Habuchi T, Knowles MA: Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 1999; 80:904-908
50. Cappellen D, Gil Diez de Medina S, Chopin D, Thiery JP, Radvanyi F: Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene 1997;14:3059-3066
51. Kagan J, Liu J, Stein JD, Wagner SS, Babkowski R, Grossman BH, Katz RL: Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer. Oncogene 1998;16:909-913
52. Hailing KC, King W, Sokolova IA, Meyer RG, Burkhardt HM, Hailing AC, Cheville JC, Sebo TJ, Ramakumar S, Stewart CS, Pankratz S, O'Kane DJ, Seelig SA, Lieber MM, Jenkins RB: A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000;164:1768-1775
53. Knowles MA: What we could do now: Molecular pathology of bladder cancer. Mol Pathol 2001;54:215-221
54. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B: Focus on bladder cancer. Cancer Cell 2004;6:111-116
55. Hovey RM, Chu L, Balazs M, DeVries S, Moore D, Sauter G, Carroll PR, Waldman FM: Genetic alterations in primary bladder cancers and their metastases. Cancer Res 1998;58: 3555-3560
56. Stoehr R, Zietz S, Burger M, Filbeck T, Denzinger S, Ober-mann EC, Hammerschmied C, Wieland WF, Knuechel R, Hartmann A: Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer. Eur Urol 2005;47:58-63
57. Baud E, Catilina P, Bignon YJ: pl6 Involvement in primary bladder tumors: Analysis of deletions and mutations. Int J Oncol 1999;14:441-445
58. Orlow I, Lacombe L, Harmon GJ, Serrano M, Pellicer I, Dal-bagni G, Reuter VE, Zhang ZF, Beach D, Cordon-Cardo C: Deletion of the pl6 and pl5 genes in human bladder tumors. J Natl Cancer Inst 1995;87:1524-1529
59. Helpap B, Schmitz-Drager BJ, Hamilton PW, Muzzonigro G, Galosi AB, Kurth KH, Lubaroff D, Waters DJ, Droller MJ: Molecular pathology of non-invasive urothelial carcinomas (part I). Virchows Arch 2003;442:309-316
60. Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, Young L, Shi SR, Gee C, Groshen S, Skinner DG, Cote RJ: Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004;22:1007-1013
61. Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, Kogevinas M, Real FX: P53 as a prognostic marker for bladder cancer: A meta-analysis and review. Lancet Oncol 2005;6:678-686
62. Linnenbach AJ, Pressler LB, Seng BA, Kimmel BS, Tomaszewski JE, Malkowicz SB: Characterization of chromosome 9 deletions in transitional cell carcinoma by mi-crosatellite assay. Hum Mol Genet 1993;2:1407-1411
63. Hartmann A, Schlake G, Zaak D, Hungerhuber E, Hofstet-ter A, Hofstaedter F, Knuechel R: Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 2002; 62:809-818
64. Knowles MA, Habuchi T, Kennedy W, Cuthbert-Heavens D: Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res 2003;63:7652-7656
65. Hornigold N, Devlin J, Davies AM, Aveyard JS, Habuchi T, Knowles MA: Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene 1999;18:2657-2661
66. Adachi H, Igawa M, Shiina H, Urakami S, Shigeno K, Hino O: Human bladder tumors with 2-hit mutations of tumor suppressor gene TSC1 and decreased expression of p27. J Urol 2003;170:601-604
67. Hopman AH, Kamps MA, Speel EJ, Schapers RF, Sauter G, Ramaekers FC: Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma. Am J Pathol 2002;161:1119-1125
68. Wilkie AO, Patey SJ, Kan SH, van den Ouweland AM, Hamel BC: FGFs, their receptors, and human limb malformations: Clinical and molecular correlations. Am J Med Genet 2002;112:266-278
69. Johnson DE, Williams LT: Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 1993;60:1-41
70. Passos-Bueno MR, Wilcox WR, Jabs EW, Sertie AL, Alonso LG, Kitoh H: Clinical spectrum of fibroblast growth factor receptor mutations. Hum Mutat 1999;14:115-125
71. van Rhijn BW, Montironi R, Zwarthoff EC, Jobsis AC, van der Kwast TH: Frequent FGFR3 mutations in urothelial papilloma. J Pathol 2002;198:245-251
72. Rieger-Christ KM, Mourtzinos A, Lee PJ, Zagha RM, Cain J, Silverman M, Libertino JA, Summerhayes IC: Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer 2003;98:737-744
73. Cappellen D, De Oliveira C, Ricol D, Gil Diez de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F: Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nature Genet 1999;23:18-20
74. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ: Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 2000; 19:3309-3320
75. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA: FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005;24:5218-5225
76. Lopez-Knowles E, Hernandez S, Malats N, Kogevinas M, Lloreta J, Carrato A, Tardon A, Serra C, Real FX: PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 2006;66:7401-7404
77. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington: SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000; 60:4152-4160
78. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, Hubbard SR, Schlessinger J: Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997;276:955-960
79. Paterson JL, Li Z, Wen XY, Masih-Khan E, Chang H, Pollett JB, Trudel S, Stewart AK: Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br J Haematol 2004;124:595-603
80. Grand EK, Chase AJ, Heath C, Rahemtulla A, Cross NC: Targeting FGFR3 in multiple myeloma: Inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia 2004;18:962-966
81. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, Stewart AK: CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005;105:2941-2948
82. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137
83. Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS: Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001;7:1957-1962
84. Neal DE, Sharpies L, Smith K, Fennelly J, Hall RR, Harris AL: The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990;65:1619-1625
85. Janmaat ML, Giaccone G: The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today (Bare) (suppl C) 2003;39:61-80
86. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimo-to RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139
87. Sordella R, Bell DW, Haber DA, Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-1167
88. Messing EM: Growth factors and bladder cancer: Clinical implications of the interactions between growth factors and their urothelial receptors. Semin Surg Oncol 1992;8:285-292
89. Coogan CL, Estrada CR, Kapur S, Bloom KJ: HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 2004;63: 786-790
90. Coombs LM, Pigott DA, Sweeney E, Proctor AJ, Eydmann ME, Parkinson C, Knowles MA: Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 1991;63:601-608
91. Sauter G, Moch H, Moore D, Carroll P, Kerschmann R, Chew K, Mihatsch MJ, Gudat F, Waldman F: Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res 1993;53:2199-2203
92. Kruger S, Weitsch G, Buttner H, Matthiensen A, Bohmer T, Marquardt T, Sayk F, Feller AC, Bohle A: HER2 overex-pression in muscle-invasive urothelial carcinoma of the bladder: Prognostic implications. Int J Cancer 2002;102:514-518
93. Ohta JI, Miyoshi Y, Uemura H, Fujinami K, Mikata K, Hosa-ka M, Tokita Y, Kubota Y: Fluorescence in situ hybridization evaluation of c-erbB-2 gene amplification and chromosomal anomalies in bladder cancer. Clin Cancer Res 2001;7: 2463-2467
94. Gardiner RA, Samaratunga ML, Walsh MD, Seymour GJ, Lavin MF: An immunohistological demonstration of c-erbB-2 oncoprotein expression in primary urothelial bladder cancer. Urol Res 1992;20:117-120
95. Sanchez-Carbayo M, Socci ND, Lozano JJ, Haab BB, Cordon-Cardo C: Profiling bladder cancer using targeted antibody arrays. Am J Pathol 2006;168:93-103
96. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C: Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006;24:778-789
97. Lu M, Wikman F, Orntoft TF, Charytonowicz E, Rabbani F, Zhang Z, Dalbagni G, Pohar KS, Yu G, Cordon-Cardo C: Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res 2002;8:171-179
98. Orntoft TF, Wolf H: Molecular alterations in bladder cancer. Urol Res 1998;26:223-233
99. Stein JP, Ginsberg DA, Grossfeld GD, Chatterjee SJ, Esrig D, Dickinson MG, Groshen S, Taylor CR, Jones PA, Skinner DG, Cote RJ: Effect of p21WAFl/CIPl expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998; 90:1072-1079
100. Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang ZF, Rosai J, Reuter VE, Pellicer A: p53 Mutations in human bladder cancer: Genotypic versus phenotypic patterns. Int J Cancer 1994;56:347-353
101. Korkolopoulou P, Christodoulou P, Kapralos P, Exarcha-kos M, Bisbiroula A, Hadjiyannakis M, Georgountzos C, Thomas-Tsagli E: The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Pathol Res Pract 1997;193:767-775
102. Simon R, Struckmann K, Schraml P, Wagner U, Forster T, Moch H, Fijan A, Bruderer J, Wilber K, Mihatsch MJ, Gasser T, Sauter G: Amplification pattern of 12ql3-ql5 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene 2002;21:2476-2483
103. Habuchi T, Kinoshita H, Yamada H, Kakehi Y, Ogawa O, Wu WJ, Takahashi R, Sugiyama T, Yoshida O: Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J Natl Cancer Inst 1994;86:1331-1335
104. Schmitz-Drager BJ, Kushima M, Goebell P, Jax TW, Gerharz CD, Bultel H, Schulz WA, Ebert T, Ackermann R: p53 and MDM2 in the development and progression of bladder cancer. Eur Urol 1997;32:487-493
105. Pfister C, Moore L, Allard P, Larue H, Lacombe L, Tetu B, Meyer F, Fradet Y: Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 1999;5:4079-4084
106. Tuna B, Yorukoglu K, Tuzel E, Guray M, Mungan U, Kirkali Z: Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer. Path Res Pract 2003; 199:323-328
107. Sanchez-Carbayo M, Socci ND, Richstone L, Corton M, Behrendt N, Wulkfuhle J, Bochner B, Petricoin E, Cordon-Cardo C: Genomic and proteomic profiles reveal the association of gelsolin to TP53 status and bladder cancer progression. Am J Pathol 2007;171:1650-1658
108. Czemiak B, Cohen GL, Etkind P, Deitch D, Simmons H, Herz F, Koss LG: Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Hum Pathol 1992;23:1199-1204
109. Fitzgerald JM, Ramchurren N, Rieger K, Levesque P, Silverman M, Libertino J A, Summerhayes IC: Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J Natl Cancer Inst 1995; 87:129-133
110. Knowles MA, Williamson M: Mutation of H-ras is infrequent in bladder cancer: Confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Cancer Res 1993;53:133-139
111. Buyru N, Tigli H, Ozcan F, Dalay N: Ras oncogene mutations in urine sediments of patients with bladder cancer. J Biochem Mol Biol 2003;36:399-402
112. Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC, Hu SX, Xu HJ, Groshen S, Taylor CR, Skinner DG, Benedict WF: Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998;58:1090-1094
113. Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, Palmer JL, Benedict WF: p53 And RB expression predict progression in Tl bladder cancer. Clin Cancer Res 1998;4: 829-834
114. Oeggerli M, Tomovska S, Schraml P, Calvano-Forte D, Schafroth S, Simon R, Gasser T, Mihatsch MJ, Sauter G: E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 2004;23:5616-5623
115. Edwards J, Duncan P, Going JJ, Watters AD, Grigor KM, Bartlett JM: Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder. J Pathol 2002;196:380-385
116. Wada T, Louhelainen J, Hemminki K, Adolfsson J, Wijk-strom H, Norming U, Borgstrom E, Hansson J, Steineck G: The prevalence of loss of heterozygosity in chromosome 3, including FHIT, in bladder cancer, using the fluorescent multiplex polymerase chain reaction. BJU Int 2001;87:876-881
117. Baffa R, Gomella LG, Vecchione A, Bassi P, Mimori K, Sedor J, Calviello CM, Gardiman M, Minimo C, Strup SE, McCue PA, Kovatich AJ, Pagano F, Huebner K, Croce CM: Loss of FHIT expression in transitional cell carcinoma of the urinary bladder. Am J Pathol 2000;156:419-424
118. Skopelitou AS, Gloustianou G, Bai M, Huebner K: FHIT gene expression in human urinary bladder transitional cell carcinomas. In Vivo 2001;15:169-173
119. Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg RC, Klopocki E, Dahl E, Wild P, Blaszyk H, Sauter G, Simon R, Schmitt R, Zaak D, Hofstaedter F, Rosenthal A, Baylin SB, Pilarsky C, Hartmann A: Deletions of chromosome 8p and loss of sFRPl expression are progression markers of papillary bladder cancer. Lab Invest 2004;84:465-478
120. Knowles MA, Shaw ME, Proctor AJ: Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatel-lite polymorphisms. Oncogene 1993;8:1357-1364
121. Tomlinson DC, L'Hote CG, Kennedy W, Pitt E, Knowles MA: Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines. Cancer Res 2005;65:10441-10449
122. Chodak GW, Hospelhorn V, Judge SM, Mayforth R, Koep-pen H, Sasse J: Increased levels of fibroblast growth factorlike activity in urine from patients with bladder or kidney cancer. Cancer Res 1988;48:2083-2088
123. Chopin DK, Caruelle JP, Colombel M, Palcy S, Ravery V, Caruelle D, Abbou CC, Barritault D: Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J Urol 1993;150:1126-1130
124. Gravas S, Bosinakou I, Kehayas P, Giannopoulos A: Urinary basic fibroblast growth factor in bladder cancer patients: Histopathological correlation and clinical potential. Urol Int 2004;73:173-177
125. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL: Two mechanisms of basic fibroblast growth factor-induced an-giogenesis in bladder cancer. Cancer Res 1997;57:136-140
126. van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Rad-vanyi F, Ooms EC, Chopin DK, Boeve ER, Jobsis AC, Zwarthoff EC: Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003;21:1912-1921
127. Maclennan GT, Kirkali Z, Cheng L: Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol 2007; 51:889-898
128. Jones TD, Cheng L: Papillary urothelial neoplasm of low malignant potential: Evolving terminology and concepts. J Urol 2006;175:1995-2003
129. Davidson DD, Cheng L: Field cancerization in the urotheli-um of the bladder. Anal Quant Cytol Histol 2006;28:337-338
130. Lopez-Beltran A: Urothelial changes induced by therapeutic procedures for bladder cancer. Anal Quant Cytol Histol 2006;28:339
131. Mazzucchelli R, Tuna B: Noninvasive urothelial neoplasms: Which classification? Anal Quant Cytol Histol 2006;28:340
132. Bhatia A, Dey P, Kumar Y: Morphometry of urinary atypical cells. Anal Quant Cytol Histol 2007;29:183-184
133. Chadwick B, Willmore-Payne C, Holden J, Layfield L: Fluorescence in situ hybridization determination of aneusomy: Criteria and technical considerations. Anal Quant Cytol Histol 2007;29:351-357
134. Lopez-Beltran A: Immunohistochemical markers in evaluation of urinary and bladder tumors. Anal Quant Cytol Histol 2007;29:121-122
135. Lopez-Beltran A, Maclennan GT, de la Haba-Rodriguez J, Montironi R, Cheng L: Research advances in apoptosis-mediated cancer therapy: A review. Anal Quant Cytol Histol 2007;29:71-78
136. Martignoni G, Brunelli M, Gobbo S, Remo A, Ficarra V, Cossu-Rocca P, Pea M, Chilosi M, Menestrina F, Cheng L: Role of molecular markers in diagnosis and prognosis of renal cell carcinoma. Anal Quant Cytol Histol 2007;29:41-49
137. Nafe R, Glienke W, Hattingen E, Schlote W, Lanfermann H, Zanella F: Correlation between amplification of the gene for the epidermal growth factor receptor (EGFR), data from preoperative proton-MR-spectroscopy (1HMRS) and histo-morphometric data of glioblastomas. Anal Quant Cytol Histol 2007;29:199-207
138. Ondracek RP, Parker F, Allen A, Davis W, Ray M, McCann W, Marshall JR: Standardization of nuclear morphometry-based biomarkers. Anal Quant Cytol Histol 2007;29:309-316
139. Requena MJ, Alvarez-Kindelan J, Blanca A: Immunohisto-chemical markers in the evaluation of tumors of the urinary bladder: A review. Anal Quant Cytol Histol 2007;29:380-382
140. Vidal-Jimenez A: New immunohistochemical markers in testicular tumors. Anal Quant Cytol Histol 2007;29:377
141. Yang Y, Zhang L, Wei Y, Wang H, Xiong W, Chen Z, Hes O, Zheng J: Detection of EWSR1 translocation with nuclear extraction-based fluorescence in situ hybridization for diagnosis of Ewing's sarcoma/primitive neuroectodermal tumor. Anal Quant Cytol Histol 2007;29:221-230